March 1, 2017 - Issue: Vol. 163, No. 36 — Daily Edition115th Congress (2017 - 2018) - 1st Session
OPIOID CRISIS AND PHARMACEUTICAL COMPANIES; Congressional Record Vol. 163, No. 36
(House of Representatives - March 01, 2017)
Text available as:
Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.
[Page H1449] From the Congressional Record Online through the Government Publishing Office [www.gpo.gov] OPIOID CRISIS AND PHARMACEUTICAL COMPANIES (Ms. MICHELLE LUJAN GRISHAM of New Mexico asked and was given permission to address the House for 1 minute and to revise and extend her remarks.) Ms. MICHELLE LUJAN GRISHAM of New Mexico. Mr. Speaker, we continue to see pharmaceutical companies put profits over people. Even though 33,000 people are dying every year due to the opioid crisis, Kaleo Pharma raised the price of a lifesaving opioid overdose medication from $690 in 2014 to $4,500 this year. The pharmaceutical industry has not only misled consumers and their providers to create a system where there are more opioid prescriptions than adults in the United States, but they are now jacking up the price of lifesaving drugs and making money on this opioid crisis that they helped, in fact, create. Meanwhile, the costs of the opioid epidemic fall on States, cities, communities, hospitals, counties, courts, and local communities who, quite frankly, do not have the resources to keep up. This is why I introduced a bill which would impose a fee on the production of opioids and use the revenue for opioid prevention, treatment, and research programs across the country. Pharmaceutical companies have to be part of solving the problem that they helped cause and to give back to the communities that opioids have ravaged. ____________________